×
About 3,264 results

ALLMedicine™ Primary Myelofibrosis Center

Research & Reviews  1,609 results

Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
https://doi.org/10.1093/ajcp/aqab027
American Journal of Clinical Pathology; Goyal T, Tu ZJ et. al.

Apr 30th, 2021 - This study seeks to further characterize the clinicopathologic spectrum of DDX41-mutated hematolymphoid malignancies. We identified DDX41 mutations from a cohort of known or suspected hematologic disorders and reviewed the corresponding clinical, ...

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: ...
https://doi.org/10.3390/curroncol28020146
Current Oncology (Toronto, Ont.); Varghese C, Immanuel T et. al.

Apr 30th, 2021 - There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). This st...

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
https://doi.org/10.1016/j.clml.2021.03.005
Clinical Lymphoma, Myeloma & Leukemia; Alshemmari SH, Rajan R et. al.

Apr 16th, 2021 - Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutatio...

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a...
https://doi.org/10.1002/ajh.26186
American Journal of Hematology; Gangat N, Guglielmelli P et. al.

Apr 12th, 2021 - Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven+...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  1,631 results

Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
https://doi.org/10.1093/ajcp/aqab027
American Journal of Clinical Pathology; Goyal T, Tu ZJ et. al.

Apr 30th, 2021 - This study seeks to further characterize the clinicopathologic spectrum of DDX41-mutated hematolymphoid malignancies. We identified DDX41 mutations from a cohort of known or suspected hematologic disorders and reviewed the corresponding clinical, ...

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: ...
https://doi.org/10.3390/curroncol28020146
Current Oncology (Toronto, Ont.); Varghese C, Immanuel T et. al.

Apr 30th, 2021 - There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). This st...

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
https://doi.org/10.1016/j.clml.2021.03.005
Clinical Lymphoma, Myeloma & Leukemia; Alshemmari SH, Rajan R et. al.

Apr 16th, 2021 - Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutatio...

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a...
https://doi.org/10.1002/ajh.26186
American Journal of Hematology; Gangat N, Guglielmelli P et. al.

Apr 12th, 2021 - Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven+...

see more →

News  23 results

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_2

Jul 15th, 2020 - Figure 1. Enlarged spleen (splenomegaly). Light micrograph of a section through an enlarged spleen that has occurred in myelofibrosis. PMF is an uncommon disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in t...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_1

Jul 15th, 2020 - Formerly known as "agnogenic myeloid metaplasia," primary myelofibrosis (PMF) is a bone marrow and blood cancer in which a clonal disorder arises from the neoplastic transformation of early hematopoietic stem cells. One of a heterogeneous group of...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699

Jul 15th, 2020 - Formerly known as "agnogenic myeloid metaplasia," primary myelofibrosis (PMF) is a bone marrow and blood cancer in which a clonal disorder arises from the neoplastic transformation of early hematopoietic stem cells. One of a heterogeneous group of...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_4

Jul 15th, 2020 - A Mayo-Careggi MPN Alliance study found that among 709 Mayo Clinic patients with PMF, 66% had a JAK2 mutation, 19% had a CALR mutation, and 5.4% had an MPL mutation. A further 10% of patients were triple-negative for these mutations. Patients with...

New JAK2 Inhibitor Approved for Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/hematology/81650

Aug 16th, 2019 - WASHINGTON -- The FDA approved the Janus kinase 2 (JAK2) inhibitor fedratinib (Inrebic) on Friday for adults with the rare bone marrow disease myelofibrosis. Support for the approval came largely from the phase III JAKARTA study, a randomized thre...

see more →